Efficacy of venlafaxine in the treatment of severe depression

Kienke, S B A Allison; Rosenbaum, Jerrold F.

doi:10.1002/1520-6394(2000)12:1+<50::aid-da6>3.0.co;2-4

Cited by 20 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…venlafaxine XR) is now available, creating an agent with a dual mechanism of action (14) and once‐daily dosing (15) that exhibits a better benefit/risk ratio than does the immediate‐release formulation (16). The pharmacology (17, 18) and therapeutic profile of this agent in the treatment of depression have been reviewed elsewhere (17, 19, 20).…”

Section: Introductionmentioning

confidence: 99%

Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors

Rudolph¹

2002

Acta Psychiatr Scand

View full text Add to dashboard Cite

Objective: To evaluate data supporting the ability of venlafaxine, an antidepressant with a dual mechanism of action, to produce remission from depression. Method: Review of multicentre, double‐blind, randomized studies comparing venlafaxine or venlafaxine extended release (XR) with a selective serotonin reuptake inhibitor (SSRI), using Hamilton Depression Rating Scale total scores in the range of ≤7 and <10 as the final outcome measure, to evaluate the ability of venlafaxine/venlafaxine XR to produce full remission from depression. Results: Venlafaxine/venlafaxine XR demonstrated higher rates of remission than did the SSRIs and placebo. Conclusion: With full remission rather than response as the measure of outcome, venlafaxine/venlafaxine XR demonstrated more robust antidepressant efficacy than the SSRIs and placebo. This finding suggests that venlafaxine/venlafaxine XR are appropriate standard‐of‐care therapies for the treatment of patients with major depressive disorder.

show abstract

Section: Introductionmentioning

confidence: 99%

Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors

Rudolph¹

2002

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…The overall score ranges from 0 to 60. However, the definition of moderate and severe depression is still a matter of debate (58,59), and reliable and clinically useful gradations based on empirical data are required, since there is evidence that different new antidepressants show distinct efficacy depending on the severity of illness (58)(59)(60).…”

Section: Discussionmentioning

confidence: 99%

Moderate/severe Depression (MADRS) Can Affect the Quality of Life and Outcome Among Patients Admitted to Breast Cancer Diagnosis Unit

Eskelinen

Selander

Ollonen

et al. 2017

View full text Add to dashboard Cite

show abstract

“…30-45 mg zur Nacht) und Venlafaxin (z.B. 75-225 mg/Tag in retardierter Form) [7,18].Aber auch selektive Serotonin-Wiederaufnahmehemmer (SSRI), z. B. Fluoxetin 20-40 mg/Tag, weisen keine oder nur geringe Bindungen am Azetylcholinrezeptor auf, sodass bei diesen Substanzen auch die Gefahr eines Harnverhalts bei Prostatavergrößerung oder anderer anticholinerger Nebenwirkungen deutlich geringer ist.…”

Section: Psychopharmakaunclassified

Psychoonkologie

Köllner

2004

Der Urologe A

View full text Add to dashboard Cite

Cancer and psychiatric symptoms commonly co-occur. The frequency is about 50%, and those most important for urology are depression, anxiety, and probably post-traumatic stress disorder. There is a strong relationship between psychological distress and cancer pain. This review provides information on diagnostic and therapeutic strategies for psychiatric diseases, which are important for oncology patients in urology. Special advice is given for the doctor-patient relationship and communication.

show abstract

Efficacy of venlafaxine in the treatment of severe depression

Cited by 20 publications

References 24 publications

Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors

Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors

Moderate/severe Depression (MADRS) Can Affect the Quality of Life and Outcome Among Patients Admitted to Breast Cancer Diagnosis Unit

Psychoonkologie

Contact Info

Product

Resources

About